Estimands: A More Strategic Approach to Study Design and Analysis

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 6, 2017, Pages 894-896

  Akacha, Mouna ^a   Kothny, Wolfgang ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DECISION MAKING; ESTIMAND; HUMAN; INTENTION TO TREAT ANALYSIS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STUDY DESIGN; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85033378768     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.872     Document Type: Note

References (5)

1. Hill, A.B. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2, 769-782 (1948).
2. European Medicines Agency (EMA). International Conference on Harmonisation. Draft ICH E9(R1) Technical Document: Estimands and Sensitivity Analysis in Clinical Trials. . Accessed 5 September 2017.
3. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials E9. . Accessed 5 September 2017.
4. Akacha, M., Bretz, F., Ohlssen, D., Rosenkranz, G. & Schmidli, H. Estimands and their role in clinical trials. Stat. Biopharm. Res. (in press).
5. Ruberg, S.J. & Akacha, M. Considerations for evaluating treatment effects from randomized clinical trials. Clin. Pharmacol. Ther. 102, 917-923 (2017).